The Association for Clinical Oncology (Association) is governed by a volunteer Board of Directors , which works to ensure that the Association achieves its mission and vision.  Voting Board members are cancer physicians and clinical researchers who volunteer their time. View the Disclosures at the bottom of each individual’s bio. Please direct any questions related to Board members' disclosures to

Chair of the Association Board

Monica M. Bertagnolli, MD, FACS, FASCO
View current ASCO disclosure here.

Monica M. Bertagnolli, MD, FACS, FASCO, is a professor of surgery at Harvard Medical School, and an associate surgeon at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. She has worked at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital since 2000. She previously served as an associate surgeon at the Strang Cancer Prevention Center in New York from 1994-2007 and as an attending surgeon at New York Presbyterian Hospital–Cornell from 1994-1999.

Since joining ASCO in 1995, Dr. Bertagnolli has served on the Society’s Board of Directors (2007-2011, 2017-present), as well as on numerous committees, including the ASCP/CAP/AMP/ASCO Colorectal Cancer Guidelines Committee (co-chair 2011-present), the Cancer Prevention Committee (2001-2004 and 2007-2010), and the Planning Committee (2008-2011), among others.  Dr. Bertagnolli currently serves as the Chair of the Society’s Board of Directors.

In addition to her ASCO involvement, Dr. Bertagnolli currently serves as vice president of Coalition of Cancer Cooperative Groups, group chair of Alliance for Clinical Trials in Oncology, president of the Alliance for Clinical Trials in Oncology Foundation, and CEO of Alliance Foundation Trials, LLC. Since 2012 she has served on the National Academy of Medicine’s National Cancer Policy Forum. In 2011, she received the Partners Healthcare Partners in Excellence Award: Personalized Cancer Medicine Partnership Team, and in 2015, she received the CEO Roundtable on Cancer Charles H. Sanders Life Sciences Award.

Dr. Bertagnolli received her undergraduate degree from Princeton University and her medical degree from the University of Utah College of Medicine; she performed her residency at Brigham and Women’s Hospital.

Association Treasurer

Jaap Verweij, MD, PhD, FASCO
View current ASCO disclosure here.

Jaap Verweij, MD, PhD, FASCO, is a medical oncologist and currently vice-Dean of the Faculty of Medicine at Erasmus University, Rotterdam, the Netherlands, as well as the Founding Dean of the Faculty of Life Sciences at the University of Siegen, Germany. Dr. Verweij has been a faculty member of Erasmus University Medical Center since 1984.

Since joining ASCO in 1986, Dr. Verweij has served on the Society’s Board of Directors, as Associate Editor of the Journal of Clinical Oncology, and as a member of the Scientific Program Committee, Conquer Cancer Foundation Grants Selection Committee, Multidisciplinary Cancer Management Committee, and Cancer Education Committee.

In addition to his ASCO involvement, Dr. Verweij currently serves as Vice-Chair of the Supervisory Board of the Dutch Cancer Foundation, a member of the Scientific Advisory Board for Aarhus University, a Fellow of The Royal Netherlands Academy of Arts and Sciences, and a member of the Supervisory Board of the Erasmus University Institute for Medical Technology Assessment. He previously served as Chair of the Supervisory Board of the Rotterdam Global Health Initiative, President of the Connective Tissue Oncology Society and for 22 years in various Board positions for the European Organisation for Research and Treatment of Cancer (EORTC), including as Vice-President, Chair of the EORTC Early Clinical Studies Group, Chair of the EORTC Soft Tissue and Bone Sarcoma Group, and Chair of the New Drug Advisory Committee. He has authored and co-authored more than 700 papers, mainly with a pharmacologic focus on new drug development.

He received his medical degree from the University of Utrecht, and completed his internship, residency, and fellowship at the Free University Hospital in Amsterdam.

Board Member

Peter C. Adamson, MD, FASCO
View current ASCO disclosure here.

Peter C. Adamson, MD, FASCO, is Chair of the Children’s Oncology Group, President of the Children’s Oncology Group Foundation, holds the Alan R. Cohen Endowed Chair in Pediatrics and is a Professor of Pediatrics and Pharmacology at Children’s Hospital of Philadelphia, Perelman School of Medicine at the University of Pennsylvania. He has been a faculty member at the University of Pennsylvania since 1999.

Since joining ASCO in 1992, Dr. Adamson has served on the Society’s Board of Directors, the Cancer Research Committee (2011-2014), the Scientific Program Committee (2007-2010), and on the Editorial Board of the Journal of Clinical Oncology (2007-2010).

In 2015 President Barack Obama appointed Dr. Adamson to the National Cancer Advisory Board. He served on Vice President Biden’s National Cancer Institute Moonshot Blue Ribbon Panel and continues to serve as an advisor to the Biden Cancer Initiative. Dr. Adamson has previously served on the American Association of Cancer Research Pediatric Steering Committee (2011-2015), the National Cancer Institute’s Experimental Therapeutics Program (NExT) Special Emphasis Panel (2012-2015), as the Chair of Children’s Oncology Group Developmental Therapeutics Program (2000-2008), on the National Cancer Institute’s Investigational Drug Steering Committee (2005-2012), and on the Department of Defense Neurofibromatosis Research Programmatic Review Committee (1999-2004).

Dr. Adamson received his undergraduate degree from Wesleyan University and his medical degree from Cornell University Medical College. He performed his residency at Children’s Hospital of Philadelphia and his fellowship in the Pediatric Oncology Branch of the National Cancer Institute.

Board Member

Howard A. “Skip” Burris, III, MD, FACP, FASCO
View current ASCO disclosure here.

Howard A. "Skip" Burris III, MD, FASCO, FACP, serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.

Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.

Dr Burris serves as the elected President of the Society and on the Board of Conquer Cancer, the ASCO Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.

Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.    

Board Member

Melissa S. Dillmon, MD, FASCO
View current ASCO disclosure here.

Melissa S. Dillmon, MD, FASCO is a medical oncologist in private practice with the Harbin Clinic, the largest multi-specialty group in Georgia, and serves on the Executive Board of Directors, the first female ever elected to this board.  She is the Department Chair of Oncology at the Tony E. Warren Cancer Center and serves on the Executive Board of Directors for GASCO (Georgia’s state oncology society).  

Since joining ASCO in 2002, she has served as the Chair of the State Affiliates Council and is the current Chair of the Government Relations Committee.  She has served on the Breast Cancer Consensus Panel, the Clinical Practice Committee, Practice Guidelines Implementation Network, the Maintenance of Certification Task Force and the Strategic Planning Task Force. Dr. Dillmon helped develop a joint guideline with ASCO and Cancer Care Ontario on Use of Adjuvant Bisphosphonates and Other Bone Modifying Agents in Breast Cancer and is working on a joint guideline for Medical Dispensing Standards with NCODA and ASCO.  She has been active in lobbying at the state and national level, attending the Advocacy Summit in 2016 and 2017 and 2019, has lobbied with ACS-CAN and ASCO for reform in Utilization Management Policies and she presented the State of Cancer Care in America in 2017 with Drs. Robin Zon and Daniel Hayes.  She was recognized as an ASCO Advocacy Champion in 2016, 2017, 2018 and 2019.  She completed the ASCO Leadership Development Program in 2011. 

Dr. Dillmon completed Leadership Georgia, a leadership program supported by the Georgia Chamber of Commerce.  She has served her community as the Chair of the Executive Board for Rome-Floyd County United Way, as a grant reviewer for the Georgia Breast Cancer License Tag program, as a leader in developing the Comprehensive Cancer Control Plan for Georgia, and as a mentor for Berry College’s Center for Integrity in Leadership.  She has been recognized as a Lead Georgia NCORP Investigator.

Dr. Dillmon graduated from Converse College with a degree in Political Science and Biology.  She received her doctorate at Wake Forest University School of Medicine and then completed her residency and fellowship at the University of Alabama-Birmingham.

Board Member

Laurie E. Gaspar, MD, MBA, FASTRO, FACR
View current ASCO disclosure here.

Laurie E. Gaspar, MD, MBA, FACR, FASTRO, grew up in Toronto, Ontario and completed medical school and a residency in radiation oncology at Western University.  Later, after moving to the United States she completed her Masters of Business Administration (MBA) at the University of Michigan.

Dr. Gaspar has been active in many national and international committees, including the ASCO Publications Committee and ASCO’s Annual Program Committees. She serves as the Society’s Treasurer.  She is also involved with the American Board of Radiology (ABR), the American Society for Radiation Oncology (ASTRO), NRG (formally RTOG), the International Society for the Study of Lung Cancer (IASLC), and SWOG. She is a Co-Chair of the NCI Thoracic Malignancy Steering Committee. Dr. Gaspar is on the editorial board of Clinical Lung Cancer and Advances in Radiation Oncology. She is the author of more than 200 published articles.

Dr. Gaspar was Professor and Chair of the Department of Radiation Oncology at the University of Colorado for more than 15 years. She is currently Professor Emerita in the Department of Radiation Oncology at the University of Colorado, as well as a staff radiation oncologist at Banner MDA in Northern Colorado.  Dr. Gaspar maintains a long-standing interest in the management of brain tumors and lung cancer.

Board Member

Maha H. A. Hussain, MD, FACP, FASCO
View current ASCO disclosure here.

Maha H. A. Hussain, MD, FACP, FASCO, is the Genevieve Teuton Professor of Medicine in the Division of Hematology Oncology, Department of Medicine, and the deputy director, and leader of the GU Oncology Program at the Robert H. Lurie Comprehensive Cancer Center of the Northwestern University Feinberg School of Medicine. 

Dr. Hussain received her medical degree from Baghdad University College of Medicine and performed her residency and fellowship at Wayne State University. 

Dr. Hussain is a practicing oncologist, internationally renowned expert and clinical researcher in genitourinary oncology particularly prostate and bladder cancer. Her research is focused on the development of novel therapeutics integrating scientific advances into clinical trials. Her clinical research has contributed to impacting the standards of care for patients with metastatic hormone sensitive and castration resistant prostate cancer.   She is also an educator and mentor and have guided the career development of many fellows and young faculty at Wayne State University and the University of Michigan several of whom have chosen an academic career in GU Oncology. 

At the national level Dr. Hussain has served in a variety of scientific leadership roles, including the Co-Chair of the SWOG Prostate Cancer Subcommittee (1994-2012), member (2009-2014) and Chair (2013-2014) of the Integration Panel of the U.S. Army Medical Research and Materiel Command Prostate Cancer Research Program, and was a member (2004-2008) and Chair (2007-2008) of the U.S. Food and Drug Administration Oncology Drug Advisory Committee.  Dr. Hussain was a member of the NCI-Cancer Biomarker Study Section and the NCI’s Prostate cancer task force.  She currently serves as an EAB member for several NCI-designated cancer centers and the UCLA Prostate Cancer SPORE.

Since joining ASCO in 1990, Dr. Hussain has served on numerous committees and boards, including the Society’s Board of Directors and the Scientific Program, Cancer Education, International Affairs, and Cancer Communications committees. In addition, she chaired the Cancer Education Committee (2008-2009), the Genitourinary Cancers Symposium Program Committee (2010-2011) and the Genitourinary Cancers Symposium Steering Committee (2013-2014) and was Associate Editor for Cancer.Net.

Dr. Hussain is the author of more than 250 scholarly articles and book chapters.  She serves/has served on the editorial boards for several national and international specialty publications.   She has been invited to give hundreds of lectures on her work in the United States and many countries around the world. 

Dr. Hussain has received many honors, including the University of Michigan Comprehensive Cancer Center Leadership Award (2007), the University of Michigan Medical School League Of Research Excellence (2011), and the 2012 Clinical & Health Services Research Award. She was elected as a Fellow of ASCO (2010). She has been named for many years in America’s Top Doctors” and “America´s Top Doctors for Cancer. In 2015 she was named one of OncLive’s Giants of Cancer Care and in 2017 she was named Castle Connolly Exceptional Women in Medicine.

Board Member

Daniel P. Mirda, MD
View current ASCO disclosure here.

Daniel P. Mirda, MD, graduated cum laude in Chemistry/Biochemistry from Cornell University in Ithaca, New York and was a proud recipient of the National Merit Scholarship Award. He received his medical degree from Stanford Medical School and did basic research as a medical student under the prestigious Medical Scholars Program at Stanford. Dr. Mirda trained at the University of California, San Francisco in Internal Medicine and also his subspecialty training in Oncology and Hematology.

He spent many years in basic scientific research at both Stanford University (1982-83) and UCSF (1988-1993), and was an Associate Professor at UCSF. In 1993, he decided to focus on clinical research and clinical medicine, where he could apply the expertise and training from his scientific career to help patients directly. His prior expertise in Oncology/Hematology research and strong clinical training have allowed him to provide the latest in Oncology/Hematology care to his patients in a compassionate setting.

Dr Mirda has been the president of the Northern California Oncology Society (ANCO) over the last 8 years, advising the California legislature on laws that will impact cancer care, patients, and their physicians. He has worked with leadership at Stanford, UCSF, UC Davis, the CMA, and AMA to protect patient rights and access to care. He has also achieved national recognition by being elected to the national oncology organizations, ASCO and ASH, serving as chairman of all the state societies in the US, coordinating and working with national experts to maintain the highest quality Oncology/Hematology care. As part of his national presence, he is frequently on national panels, presenting to Medicare, NCCN, ASCO and ASH, representing the practicing physicians across the country.

Dr. Mirda has many academic awards, extensive teaching experience, and has participated on the board of directors of several charitable foundations. As part of his role as State Oncology Society President, Dr. Mirda participates in state of the art teaching conferences organized for oncologists and hematologists to remain current with the latest in oncology and hematology care. He continues to support the community with seminars for local patient support groups and charitable organizations such as the American Cancer Society and the Leukemia and Lymphoma Society of Sonoma County.

Board Member

Lori J. Pierce, MD, FASTRO, FASCO
View current ASCO disclosure here.

Lori J. Pierce, MD, FASTRO, FASCO is a radiation oncologist, professor, and Vice Provost for Academic and Faculty Affairs at the University of Michigan. She is also director of the Michigan Radiation Oncology Quality Consortium. A national leader in breast cancer research, Dr. Pierce was previously a Senior Investigator at the National Cancer Institute, National Institutes of Health and in 1992, joined the faculty at the University of Michigan where she has focused her career primarily on the treatment of breast cancer.

An active ASCO member since 1992, Dr. Pierce is a past member of multiple Society committees including the Government Relations Committee, Annual Meeting Scientific Program Committee and the Conquer Cancer Foundation Nominating Committee, and she served as a mentor for the Leadership Development Program from 2015 to 2018. She was named a Fellow of ASCO (FASCO) in 2015.  She is the Society’s President-Elect.

With over 160 manuscripts and book chapters published, Dr. Pierce has received numerous teaching and leadership awards. In 2018, she received the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. Most recently, Dr. Pierce was selected as the 2019 Woman of the Year by the United Way of Washtenaw County (UWWC) Women United  Group of Michigan.

Dr. Pierce completed her undergraduate degree in biomedical engineering at the University of Pennsylvania and her medical degree at Duke University. She completed her internship at the Thomas Jefferson University Hospital and her residency at the University of Pennsylvania.

Board Member

Blase N. Polite, MD, MPP, FASCO
View current ASCO disclosure here.

Blase N. Polite, MD, MPP, FASCO, is Associate Professor of Medicine; Deputy Section Chief for Clinical Operations and Executive Medical Director for Cancer Accountable Care at the University of Chicago, where he currently oversees the negotiations and implementation of several alternative payment models for the cancer center. He is Past-Chair of the Society’s Health Disparities Committee and a two-time chair of the Government Relations Committee (GRC), and currently serves on the Society’s Board of Directors. He is a graduate of ASCO’s Leadership Development Program, a recipient of an ASCO Career Development Award (CDA), and was named a Fellow of the Society in 2018. He is currently an Associate Editor of the Journal of Oncology Practice. Dr. Polite is an active practicing GI oncologist, specializing in the treatment of patients with colorectal and anal cancer. He received a distinguished clinician award from the Biologic Science Division faculty and distinguished teaching award from the oncology fellows.

During his tenure on the Government Relations Committee, Dr. Polite helped lead the rapid growth in ASCO’s advocacy efforts where ASCO was intimately involved in the development and implementation of MACRA and the 21st Century Cures Act. He also helped lead the rapid expansion of ASCO’s state advocacy efforts. He serves on the ASCO alternative payment models and value based care taskforces, where he helped lead the development of a cancer Alternative Payment Model being submitted for consideration by the Physician-Focused Payment Model Technical Advisory Committee (PTAC) established under MACRA. He has been a lead author on several important ASCO policy statements related to drug pricing, health reform policy, Medicaid policy, and 340B system reform. He also led a multi-organization work group of AACR, ACS, NCI, and ASCO to produce and simultaneous publish in all the organization’s major journals a statement about the future of health disparities research.

Dr. Polite earned his Bachelor and Master’s degree in Public Policy Studies from the University of Chicago, and previously served with the Department of Health and Human Services as well as with the Office of Senator Bill Bradley in Washington, DC, on dedicated efforts directed at healthcare and Medicare reform policy. He received his MD from Indiana University and later completed his training in Internal Medicine and medical oncology at the University of Chicago.

Non-Voting Board Member- Chief Executive Officer

Clifford A. Hudis, MD, FACP, FASCO
View current ASCO disclosure here.

Clifford A. Hudis, MD, FACP, FASCO is the Chief Executive Officer of  the Association for Clinical Oncology. He also serves as the Chief Executive Officer of the American Society of Clinical Oncology and Conquer Cancer, the ASCO Foundation, and as the Chairman of the Board of Governors of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of roles at ASCO, including as President during the Society’s 50th anniversary year (2013-14). Before transitioning full-time to ASCO, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City, where he was also Professor of Medicine at the Weill Medical College of Cornell University. In this role, he developed more effective treatments for all stages of breast cancer, while also exploring novel prevention opportunities. As CEO, Dr. Hudis’ focus is on education, research and promotion of the highest quality of care by ASCO’s nearly 45,000 members. Key initiatives include the acceleration of CancerLinQ, ASCO’s focused effort to increase insights and learning from the rapidly accumulating electronic records of routine care provided by clinicians.